Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database

Lee, Lui Shiong; Elhage, Oussama; Trock, Bruce J.; Ehdaie, Behfar; Carroll, Peter R.; Filson, Christopher P.; Logothetis, Christopher J.; Morgan, Todd M.; Klotz, Laurence; Pickles, Tom; Hyndman, Eric; Moore, Caroline M.; Gnanapragasam, Vincent; Hemelrijck, Mieke Van; Villers, Arnauld; Robert, G.; Semjonow, Axel; Rannikko, Antti; Valdagni, Riccardo; Perry, Antoinette S.; Hugosson, Jonas; Rubio‐Briones, J.; Hefermehl, Lukas; Shiong, Lee Lui; Frydenberg, Mark; Stricker, Phillip D.; Sugimoto, Mikio; Chung, Byung Ha; Kwast, Theo van der; Linden, Wim van der; Hulsen, Tim; Ruwe, Boris; Hooft, Peter van; Steyerberg, Ewout; Beckmann, Kerri; Denton, Brian T.; Hayen, Andrew; Boutros, Paul C.; W, Guo; Benfante, Nicole; Cowan, Janet E.; Patil, Dattatraya; Park, Lauren; Ferrante, Stephanie; Mamedov, Alexandre; Lapointe, Vincent; Crump, Trafford; Stavrinides, Vasilis; Kimberly-Duffell, Jenna; Santaolalla, Aida; Nieboer, Daan; Olivier, Jonathan; Rancati, T.; Ahlgren, Helén; Mascarós, Juanma; Löfgren, Annica; Lehmann, Kurt; Lin, Chin‐Chung; Cusick, Thomas W.; Hirama, Hiromi; Lee, Kwang Suk; Jenster, Guido; Auvinen, Anssi; Bjartell, Anders; Haider, Masoom A.; Bochove, Kees van; Kouspou, Michelle M.; Paich, Kellie; Bangma, Chris H.; Roobol, Monique J.; Helleman, Jozien

doi:10.1016/j.euros.2021.09.012

Cited by 4 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…79 However, stratifying by ethnicity among 9,158 patients in the GAP3 Global Consortium Database and 1,315 in the Canary Prostate Active Surveillance Study, no differences were observed in progression to treatment by ethnicity (White, African/Afro-Caribbean/black, or Asian). 80,81 Finally, Catalona and colleagues examined 7,279 patients who underwent germline genetic analysis and found no significant association between time to progression and genetic ancestry or self-reported race. 82 Overall, the preponderance of data suggests that race/ethnicity appears to account for a small proportion of variation in AS outcomes and should not be used as a selection criterion for AS.…”

Section: As Of Localized Pcamentioning

confidence: 99%

Incorporating Genetic Risk Into Prostate Cancer Care: Implications for Early Detection and Precision Oncology

Amini,

Salari

2024

JCO Precis Oncol

View full text Add to dashboard Cite

The availability and cost of germline and somatic genetic testing have dramatically improved over the past two decades, enabling precision medicine approaches in oncology, with significant implications for prostate cancer (PCa) care. Roughly 12% of individuals with advanced disease are carriers of rare pathogenic germline variants that predispose to particularly aggressive and earlier-onset disease. Several of these variants are already established as clinically actionable by modern precision oncology therapeutics, while others may come to aid the selection of active surveillance, definitive local therapies, and systemic therapies. Concurrently, the number of common variants (ie, incorporated into polygenic risk scores) associated with PCa risk has continued to grow, but with several important considerations both at the intersection of race and ancestry and for early detection of aggressive disease. Family history has historically been used as a proxy for this inherited genetic risk of PCa, but recently emerging evidence examining this relation has shifted our understanding of how best to leverage this tool in PCa care. This review seeks to clarify and contextualize the existing and emerging precision oncology paradigms that use inherited genetic risk in PCa care, for both early detection and localized disease management.

show abstract

Section: As Of Localized Pcamentioning

confidence: 99%

Incorporating Genetic Risk Into Prostate Cancer Care: Implications for Early Detection and Precision Oncology

Amini,

Salari

2024

JCO Precis Oncol

View full text Add to dashboard Cite

show abstract

Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer—A Report of a Movember International Consensus Meeting

Moore

King

Withington

et al. 2023

European Urology Oncology

View full text Add to dashboard Cite

Five-Year Prospective Observational Study of African-American Men on Active Surveillance for Prostate Cancer Demonstrates Race Is Not Predictive of Oncologic Outcomes

et al. 2022

View full text Add to dashboard Cite

Introduction This study aimed to evaluate if race impacted outcomes or risk of disease progression in men on active surveillance (AS) for prostate cancer. We present the results from our majority African-American cohort of men in an equal access setting over a 5-year follow-up period. Patients and Methods All patients who elected AS for prostate cancer at the Southeast Louisiana Veterans Health Care System are entered into a prospectively managed observational database. Patients were divided into groups based on self-reported race. Grade group progression was defined as pathologic upgrading above International Society of Urological Pathology Grade Group 1 disease on subsequent biopsies following diagnostic biopsy. All tests were 2 sided using a significance of .05. Results A total of 228 men met inclusion criteria in the study, including 154 non-Hispanic African American and 74 non-Hispanic Caucasian American men, with a median follow-up of 5 years from the initiation of AS. Race was not predictive of Gleason grade progression, AS discontinuation, or biochemical recurrence on Cox multivariate analysis (HR = 1.01, 0.94, 0.85, P = .96, .79, .81, respectively). On Kaplan-Meier analysis at 5 years, African-American progression-free, AS discontinuation free, and overall survival probability was comparable to their Caucasian American counterparts (P > .05 for all). Conclusions Active surveillance is a safe treatment option for low and very low risk prostate cancer, regardless of race. African-American and Caucasian-American men did not have any significant difference in Gleason grade group progression in our cohort with 5-year follow-up.

show abstract

Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database

Cited by 4 publications

References 29 publications

Incorporating Genetic Risk Into Prostate Cancer Care: Implications for Early Detection and Precision Oncology

Incorporating Genetic Risk Into Prostate Cancer Care: Implications for Early Detection and Precision Oncology

Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer—A Report of a Movember International Consensus Meeting

Five-Year Prospective Observational Study of African-American Men on Active Surveillance for Prostate Cancer Demonstrates Race Is Not Predictive of Oncologic Outcomes

Contact Info

Product

Resources

About